Changes And Clinical Value Of Neurofilament Light Chain As A Biomarker In Patients With Multiple Sclerosis

Objective:THE levels of Neurofilament Light Chain by Smoia and 3.0T head and spinal MRI to compare the number of T2 lesions,EDSS score progression to explore the potential of neurofibromin as disease progression and effective biomarkers in patients with MS.Method :Patients with Ms including Clinically isolated Syndrome group 、Relapsing remitting Multiple Sclerosis group and the Secondary Prog-ressive Multiple Sclerosis group were enrolled in this study from September 2019 to December 2020 in our department of Neurology for long-term follow-up.The levels of serum neurofilament protein were detected by Smoia method.The difference of sNFL expression level among subgroups was analyzed.The correlation of sNFL expression level with age,duration of disease,disability score（EDSS）and the number of lesions on T2 wi was analyzed.Results:A total of 24 patients with MS were enrolled in this study,including4 patients in the CIS group,14 patients in the RRMS group,and 6patients in the SPMS group.There were no significant differences in age,sex and treatment among the three subgroups（p>0.05）,but there were significant differences in the duration of disease,EDSS score and the number of t 2 lesions among the three subgroups（p<0.01）.When analyzing the difference of sNFL expression level in each subgroup,there was no significant difference in sNFL expression level between CIS group and RRMS Group（p=0.202）,but there was a difference between CIS group and SPMS Group（p=0.021）,and there was a significant difference between RRMS group and SPMS group（p=0.008）.The expression of SNFL was not correlated with age（p=0.062）,but was significantly correlated with the duration of MS,the number of lesions on T2 and EDSS score（p<0.01）.Conclusion:1.sNFL has a higher expression level in progressive MS,which can identify the disease progression of MS,but it cannot be used as a standard to distinguish different subtypes at present.2.The expression level of sNFL is well correlated with the imaging evidence and disability progression of MS patients,and is an important biological marker for evaluating the disease progression and treatment response of MS patients.3.sNFL is an effective complementary means for MS assessment in early MS patients without significant progress in EDSS score,and has the potential as a biomarker for assessing No Evidence of disease Activity status.